# Soufflé Therapeutics

> Receptor-targeted RNA medicines designed to reach tissues beyond the liver.

## Why it is interesting

The investment case depends on making extrahepatic RNA delivery reproducible across programs, not simply designing a potent RNA payload. Human safety, delivery and durability data remain the decisive milestones.

## Profile

- **Latest funding:** Series B — $135M (October 13, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $135M
- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-10-15
- **Latest funding investors:** Juvia Group, TCG Crossover Management, BB Biotech, Fidelity Management & Research, Balyasny Asset Management, Unnamed sovereign wealth fund, ARCH Venture Partners, Bessemer Venture Partners, Amgen Ventures, Breyer Capital, The Invus Group, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, Temasek, Vida Ventures

## Key facts

- Closed an oversubscribed $135M Series B on October 13, 2026.
- Bayer collaboration announced January 2026 is distinct from equity financing.

## Funding history

- Series B · $135M · October 13, 2026
  Source: https://www.souffletx.com/news/press-releases/101326/

## Investors in our directory

- https://venturecapitaltracker.com/fund/juvia-group
- https://venturecapitaltracker.com/fund/tcgx
- https://venturecapitaltracker.com/fund/bessemer-venture-partners
- https://venturecapitaltracker.com/fund/arch-venture-partners

## Related articles

- https://venturecapitaltracker.com/souffle-therapeutics-135m-series-b-rna-delivery

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/souffle-therapeutics